All Pharma News
Catalyst Pharma Announces Settlement of U.S. Patent Litigation and Resolution

Catalyst Pharma Announces Settlement of U.S. Patent Litigation and Resolution
GLOBENEWSWIRE
12 Jul 2022
Share Share
Catalyst Pharma Reports that Ruzurgi`s FDA Marketing Approval is No Longer Valid

Catalyst Pharma Reports that Ruzurgi`s FDA Marketing Approval is No Longer Valid
GLOBENEWSWIRE
03 Feb 2022
Share Share
Jacobus Pharm`s New Drug, Ruzurgi (Amifampridine) Receives approval in the U.S.

Jacobus Pharm`s New Drug, Ruzurgi (Amifampridine) Receives approval in the U.S.
FDA
01 Feb 2022
Share Share
Catalyst Pharma Receives Issuance of Mandate by the U.S. Court of Appeals

Catalyst Pharma Receives Issuance of Mandate by the U.S. Court of Appeals
GLOBENEWSWIRE
28 Jan 2022
Share Share
Enforcement Report - Week of October 6, 2021

Enforcement Report - Week of October 6, 2021
FDA
06 Oct 2021
Share Share
Catalyst one-ups Jacobus, FDA in Firdapse exclusivity appeal

Catalyst one-ups Jacobus, FDA in Firdapse exclusivity appeal
K. Dunleavy FIERCEPHARMA
02 Oct 2021
Share Share
Jacobus Pharmaceuticals Issues Voluntary Worldwide Recall of Ruzurgi 10 mg

Jacobus Pharmaceuticals Issues Voluntary Worldwide Recall of Ruzurgi 10 mg
FDA
13 Sep 2021
Share Share
An incensed Catalyst Pharma sues the FDA

An incensed Catalyst Pharma sues the FDA
Natalie Grover ENDPTS
13 Jun 2019
Share Share
Jacobus prices its rare disease drug at half of what Catalyst charges

Jacobus prices its rare disease drug at half of what Catalyst charges
Ed Silverman STAT NEWS
12 Jun 2019
Share Share
Is Jacobus poised to win physician, payer support for off-label adult LEMS use?

Is Jacobus poised to win physician, payer support for off-label adult LEMS use?
Natalie Grover ENDPTS
11 Jun 2019
Share Share